Inotiv Inc is a leading provider of preclinical and clinical research services, specializing in laboratory animal research and drug development solutions for the pharmaceutical and biotechnology industries
The company offers a wide range of scientific services, including toxicology, pathology, and pharmacology, aimed at helping clients navigate the complexities of medical research and bring new therapies to market. By leveraging advanced technologies and expertise, Inotiv supports clients in designing and executing studies that ensure the safety and efficacy of therapeutic products, thereby advancing healthcare innovation.
The law firm of Kirby McInerney LLP is investigating potential claims against Inotiv, Inc. (“Inotiv” or the “Company”) (NASDAQNOTV). The investigation concerns whether Inotiv and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Inotiv, Inc. (“Inotiv” or the “Company”) (NASDAQNOTV) on behalf of Inotiv stockholders. Our investigation concerns whether Inotiv has violated the federal securities laws and/or engaged in other unlawful business practices.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Inotiv, Inc. (NasdaqCM: NOTV).
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Inotiv, Inc. (NasdaqCM: NOTV).
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Inotiv, Inc. (NASDAQNOTV) on behalf of long-term stockholders following a class action complaint that was filed against Inotiv on June 23, 2022 with a Class Period from September 21, 2021 to November 16, 2022. Our investigation concerns whether the board of directors of Inotiv have breached their fiduciary duties to the company.
WEST LAFAYETTE, Ind., July 24, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQNOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2023 third quarter ended June 30, 2023, on Thursday, August 10, 2023, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.
WEST LAFAYETTE, Ind., May 25, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will present at the Jefferies Healthcare Conference, being held in New York, NY, from June 7-9, 2023. Management will also be available for one-on-one meetings.
WEST LAFAYETTE, Ind., May 19, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today its participation in the following investor conferences:
WEST LAFAYETTE, Ind., May 04, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, and research models and related products and services, announced today the expansion of the Company’s safety pharmacology offering with the validation and verification of a cardiopulmonary telemetry study model in cynomolgus macaques. Offered through Inotiv’s Discovery and Safety Assessment business, telemetry allows for the continuous observation of ECG, respiratory rate and volume, blood pressure and other cardiovascular parameters during preclinical safety studies.
WEST LAFAYETTE, Ind., April 26, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQNOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2023 second quarter ended March 31, 2023, on Thursday, May 11, 2023, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.
San Diego, CA -- (SBWIRE) -- 04/17/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Inotiv, Inc.
WEST LAFAYETTE, Ind., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQNOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2023 first quarter ended December 31, 2022 on Monday, February 13, 2023 after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Inotiv, Inc. (NasdaqCM: NOTV).
WEST LAFAYETTE, Ind., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQNOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that it has earned the 2023 Top Workplaces USA award, issued by Energage, a purpose-driven organization that develops solutions to build and brand Top Workplaces. The Top Workplaces program has a 15-year history of surveying more than 20 million employees and recognizing the top organizations across 60 markets for regional Top Workplaces awards.
WEST LAFAYETTE, Ind., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQNOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that David Landman has been designated by Jermyn Street Associates LLC as its Shareholder Representative on the Board of Directors, replacing Scott Cragg, who is stepping down to focus on his position as Partner at AS Birch Grove.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Inotiv, Inc. (NasdaqCM: NOTV).
WEST LAFAYETTE, Ind., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQNOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the Company will issue its financial results press release for the fiscal 2022 fourth quarter and full year ended September 30, 2022 on Tuesday, January 10, 2023 after the close of the stock market. The Company will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results.
San Diego, CA -- (SBWIRE) -- 12/09/2022 -- Inotiv, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
WEST LAFAYETTE, Ind., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQNOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today the opening of the second phase of its lab facility in Rockville, MD, the scheduled opening date of January 2023 for its pathology campus and training center in Kalamazoo, MI, and the opening and occupancy of the site expansion at its facility in Boulder, CO. These openings and expansions reflect the Company’s ongoing initiatives to broaden its portfolio of pre-clinical and clinical service offerings.
WEST LAFAYETTE, Ind., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQNOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced plans to close two isolator facilities in Indianapolis, Indiana, and consolidate them with existing facilities in the U.S. The Company’s subsidiaries in France and the U.K. have also proposed a consolidation plan of two facilities in Gannat, France, and Blackthorn, Bicester U.K., into existing facilities. The Company also provided an update on its previously announced site optimization plans in Virginia, Michigan, and Pennsylvania.
WEST LAFAYETTE, Ind., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQNOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the Company will issue its financial results press release for the fiscal 2022 fourth quarter ended September 30, 2022, on Monday, December 12, 2022, after the close of the stock market. The Company will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results.
